Correction: Norcantharidin Inhibits Renal Interstitial Fibrosis by Blocking the Tubular Epithelial-Mesenchymal Transition

Ying Li,Yan Sun,Fuyou Liu,Lin Sun,Jun Li,Shaobin Duan,Hong Liu,Youming Peng,Li Xiao,Yuping Liu,Yiyun Xi,Yanhua You,Hua Li,Min Wang,Shuai Wang,Tao Hou
DOI: https://doi.org/10.1371/annotation/84e623b5-d1a7-47b7-96d7-4f5464b6f4b3
IF: 3.7
2013-01-01
PLoS ONE
Abstract:Epithelial-mesenchymal transition (EMT) is thought to contribute to the progression of renal tubulointerstitial fibrosis.Norcantharidin (NCTD) is a promising agent for inhibiting renal interstitial fibrosis.However, the molecular mechanisms of NCTD are unclear.In this study, a unilateral ureteral obstruction (UUO) rat model was established and treated with intraperitoneal NCTD (0.1 mg/kg/day).The UUO rats treated with NCTD showed a reduction in obstruction-induced upregulation of a-SMA and downregulation of E-cadherin in the rat kidney (P,0.05).Human renal proximal tubule cell lines (HK-2) stimulated with TGF-b 1 were treated with different concentrations of NCTD.HK-2 cells stimulated by TGF-b 1 in vitro led to downregulation of E-cadherin and increased de novo expression of a-SMA; co-treatment with NCTD attenuated all of these changes (P,0.05).NCTD reduced TGF-b 1 -induced expression and phosphorylation of Smad2/3 and downregulated the expression of Snail1 (P,0.05).These results suggest that NCTD antagonizes tubular EMT by inhibiting the Smad pathway.NCTD may play a critical role in preserving the normal epithelial phenotype and modulating tubular EMT.
What problem does this paper attempt to address?